Apolipoprotein‐M bound sphingosine‐1 phosphate enhances heparan sulfate expression and endothelial nitric oxide synthase phosphorylation in cultured endothelial cells

Abstract

Sphingosine‐1 phosphate (S1P) is blood borne bioactive sphingolipid metabolite that has protective properties against microvascular leakage under inflammatory conditions and also can promote endothelial NO production. Previous investigations suggest that functions are mediated by S1P receptor‐1 (S1pr1) but are also limited by action of S1P on other S1P receptors. Apolipoprotein‐M (ApoM), which has been shown to act as a carrier of S1P, may help target S1P to S1pr1, producing biased S1pr1 signaling. In the current study, we hypothesized that combination of ApoM will improve the ability of S1P to enhance 1) endothelial barrier function, and 2) phosphorylation of eNOS on its activation site. We used confluent monolayers of human umbilical vein endothelial cells (HUVEC) to model the endothelial barrier. Transendothelial electrical resistance (TER), determined by electric cell‐substrate impedance sensing, served as an indicator of barrier function. Because endothelial glycocalyx health is related to barrier function, we also determined the degree of heparan sulfate expression on the cell surface, visualized by immunofluorescence microscopy of fixed, non‐permeabilized HUVEC. Western blotting was used to measure eNOS phosphorylation on its activation site (S1177). These endpoints were evaluated in control cells and cells that were treated with ApoM (0.5 μM), S1P (1 μM), or the combination of both. The results show that the addition of ApoM‐bound S1P to HUVEC significantly increased and sustained the increase in TER of the HUVEC monolayers compared to the vehicle and S1P alone. ApoM‐bound S1P also increased heparan sulfate expression on the plasma membrane and elicited enhanced phosphorylation of eNOS on S1177 compared to either ApoM or S1P alone. Collectively, the findings support that ApoM enhances the ability of S1P to promote endothelial barrier function, surface heparan sulfate expression, and activation of eNOS. These findings suggest high potential for using ApoM‐bound S1P as a therapeutic target for ameliorating endothelial dysfunction.Support or Funding InformationThis work was supported by NIH R01GM120774 and American Heart Association 18UFEL33960365. Tabitha E. Norton and Taylor E. Collignon contributed equally to this work.